Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Dysfunction Clear all
Completed Phase 2 Interventional Results available

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Anakinra, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jun 10, 2026, 6:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kidney Disease After COVID-19

NCT05328986
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Chronic Kidney Injury
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,753 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

NCT00496483
View directory record Official record
Conditions
Renal Failure
Interventions
LCP Tacro (tacrolimus), Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Jun 10, 2026, 6:14 PM EDT
Completed No phase listed Observational

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

NCT05611905
View directory record Official record
Conditions
Renal Excretion, Bacterial Infections, Inflammatory Disease, Oncologic Disease
Interventions
11C-para-aminobenzoic acid PET/CT, Probenecid
Combination Product · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated No phase listed Observational

APOL1 Gene Variants in African American Kidney Transplant Recipients

NCT01442402
View directory record Official record
Conditions
Transplant;Failure,Kidney, Kidney Disease, Kidney Failure, Chronic
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated Phase 1 Interventional Results available

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

NCT05510245
View directory record Official record
Conditions
Type 2 Diabetes, Renal Impairment
Interventions
PF-07081532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

NCT00915200
View directory record Official record
Conditions
Diabetic Nephropathies, Proteinuria, Oxidative Stress
Interventions
N-acetylcysteine, silibin, high-dose silibin, N-acetylcysteine placebo, silibin placebo
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

NCT01810939
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Hyperkalemia (HK)
Interventions
Patiromer, Placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
14
States / cities
Azusa, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional

Comparison of Bovine Carotid Artery and Expanded Polytetrafluoroethylene (ePTFE) for Permanent Hemodialysis Access

NCT01021839
View directory record Official record
Conditions
Kidney Failure, Renal Dialysis
Interventions
Grafts placement
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2009 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

NCT01833754
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jun 10, 2026, 6:14 PM EDT
Withdrawn No phase listed Observational

Prediction of Expected Length of Hospital Stay Using Machine Learning

NCT04784351
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

NCT04237831
View directory record Official record
Conditions
Renal Failure
Interventions
BMS-986259
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Jun 10, 2026, 6:14 PM EDT
Completed No phase listed Observational

Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease

NCT01530945
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Jun 10, 2026, 6:14 PM EDT
Active, not recruiting Not applicable Interventional

Pain Reduction Using NEurostimulation Study

NCT05311956
View directory record Official record
Conditions
End Stage Kidney Disease, Chronic Pain
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

NCT07429045
View directory record Official record
Conditions
Overweight and Obesity
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
5
States / cities
Lake Forest, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional

Treatment Choice and Outcomes for ESRD: Evidence From the First Year of a Nationwide Randomized Evaluation

NCT05005572
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Payment adjustment for home dialysis and transplant
Other
Lead sponsor
Amy Finkelstein
Other
Eligibility
66 Years and older
Enrollment
18,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

NCT05469100
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Anaheim, California • Pleasanton, California • Tustin, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jun 10, 2026, 6:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906
View directory record Official record
Conditions
Prevention of Rejection in Kidney Transplant
Interventions
AT-1501
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jun 10, 2026, 6:14 PM EDT
Not listed Phase 2 Interventional

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

NCT05222191
View directory record Official record
Conditions
Renal Insufficiency, Chronic Hypertension
Interventions
Spironolactone, Chlorthalidone, Placebo
Drug
Lead sponsor
Indiana Institute for Medical Research
Other
Eligibility
19 Years to 110 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

NCT06675175
View directory record Official record
Conditions
Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
Interventions
AZD4144, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Glendale, California • Daytona Beach, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional

Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in CKD Patients

NCT01324193
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Pomegranate extracts
Dietary Supplement
Lead sponsor
Kenneth Wilund
Other
Eligibility
30 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated Phase 1Phase 2 Interventional

Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis

NCT00086164
View directory record Official record
Conditions
Hyperplasia, Chronic Renal Failure
Interventions
edifoligide (E2F Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
21
States / cities
Los Angeles, California • Hudson, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2005 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

NCT00721734
View directory record Official record
Conditions
Multiple Myeloma, Renal Insufficiency
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional Results available

IMPROVE AKI Cluster-Randomized Trial

NCT03556293
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AKI Prevention Toolkit, Technical Assistance (TA), Virtual Learning Collaborative (VLC), Automated Surveillance Reporting (ASR)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
10,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jun 10, 2026, 6:14 PM EDT